We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breast Tumors That Display Kataegis Have a Better Prognosis

By LabMedica International staff writers
Posted on 12 Jul 2016
Breast tumors that display kataegis, a state of hypermutation that is localized to only a few genomic regions, are not highly invasiveness, and patients with cancers that possessing this marker have a good prognosis.

Kataegis is a mutational process observed in approximately 55% of breast tumors that results in hypermutation in localized genomic regions. More...
Investigators at the University of California, San Diego (USA) used whole-genome sequence data of 97 tumors to examine the distribution of kataegis loci.

The data they obtained revealed that these somatic mutations were over-represented on chromosomes 8, 17, and 22 and depleted on chromosomes 2, 9, and 16 and were enriched in regions containing genes and functional regulatory elements. Genes in the vicinity of kataegis loci were less likely to be aberrantly expressed than genes that were located farther away. Breast cancers that contained kataegis had a transcriptome-wide expression signature that was consistent with low invasive potential and enabled the kataegis status of a tumor to be predicted using RNA sequencing (RNA-seq) data.

The investigators exploited the kataegis expression signature to predict kataegis status in 412 breast cancers with transcriptome but not whole-genome sequence data and showed that kataegis loci were enriched in high-grade, HER2+ tumors in patients diagnosed with breast cancer at an older age and who had a later age at death.

“We do not know what causes kataegis, and before this study not much was known about its functional importance at the molecular or clinical level,” said senior author Dr. Kelly Frazer, professor of pediatrics at the University of California, San Diego. “We have now found that kataegis is associated with a good prognosis for patients with breast cancer. Kataegis status might also be helpful in determining a patient’s treatment options, but there is a long way to go before kataegis status could be used in the clinic.”

The paper on kataegis in breast tumors was published in the June 30, 2016, online edition of the journal Cell Reports.

Related Links:
University of California, San Diego



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PBC Assay
Primary Biliary Cholangitis Assays
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New automated lab procedures can detect opioids in tiny amounts of blood (Photo courtesy of Tripathi Lab/Brown University)

First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns

As the opioid crisis continues to impact communities across the United States, laboratories encounter significant difficulties in accurately detecting opioid substances in individuals with opioid use disorder.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more

Microbiology

view channel
Image: A prototype of the lateral flow test (Photo courtesy of University of Exeter)

POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques

Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.